Sec. 28-33. Prescription drug shortage task force. Study. Recommendations.
Sec. 28-33. Prescription drug shortage task force. Study. Recommendations. (a) There is established a task force to study emergency preparedness and mitigation strategies for prescription drug shortages. The task force shall identify prescription drugs at risk of shortage in this state and make recommendations pursuant to subsection (g) of this section.
(b) The task force shall consist of the following members:
(1) Two appointed by the speaker of the House of Representatives, one of whom has expertise in prescription drug supply chains and one of whom has expertise in federal law concerning prescription drug shortages;
(2) Two appointed by the president pro tempore of the Senate, one of whom represents hospitals and one of whom represents health care providers who treat patients with rare diseases;
(3) One appointed by the majority leader of the House of Representatives, who represents one of the two federally recognized Indian tribes in the state;
(4) One appointed by the majority leader of the Senate, who represents one of the two federally recognized Indian tribes in the state;
(5) One appointed by the minority leader of the House of Representatives, who represents health insurance companies;
(6) One appointed by the minority leader of the Senate, who is a representative of the Connecticut Health Insurance Exchange;
(7) The Commissioner of Health Strategy, or the commissioner's designee;
(8) The Commissioner of Consumer Protection, or the commissioner's designee;
(9) The Commissioner of Social Services, or the commissioner's designee;
(10) The Commissioner of Public Health, or the commissioner's designee;
(11) The chief executive officer of The University of Connecticut Health Center, or the chief executive officer's designee;
(12) The Insurance Commissioner, or the commissioner's designee;
(13) The Commissioner of Economic and Community Development, or the commissioner's designee; and
(14) Any other members as deemed necessary by the chairpersons of the task force.
(c) Any member of the task force appointed under subdivision (1), (2), (3), (4), (5) or (6) of subsection (b) of this section may be a member of the General Assembly.
(d) All initial appointments to the task force shall be made not later than thirty days after July 8, 2025. Any vacancy shall be filled by the appointing authority.
(e) The speaker of the House of Representatives and the president pro tempore of the Senate shall select the chairpersons of the task force from among the members of the task force. Such chairpersons shall schedule the first meeting of the task force, which shall be held not later than sixty days after July 8, 2025.
(f) The administrative staff of the joint standing committee of the General Assembly having cognizance of matters relating to general law shall serve as administrative staff of the task force.
(g) Not later than January 1, 2026, and annually thereafter, the task force shall submit a report on its findings and recommendations to the joint standing committees of the General Assembly having cognizance of matters relating to general law, human services, insurance and real estate and public health, in accordance with the provisions of section 11-4a, including, but not limited to, identification of prescription drugs the task force determines are at risk of shortage and strategies that would mitigate these shortages, including methods to increase in-state production of such drugs deemed both at risk of shortage and critically necessary for the provision of health care within the state.
(P.A. 25-167, S. 5.)
History: P.A. 25-167 effective July 8, 2025.
| (Return to Chapter Table of Contents) |
(Return to List of Chapters) |
(Return to List of Titles) |